fig1
![Pharmacogenetic and pharmacogenomic discovery strategies](https://image.oaes.cc/866ad8d2-af6e-4525-a533-49ed80b40555/3059.fig.1.jpg)
Figure 1. Pharmacogenetic biomarkers in FDA drug labels over the last decade (www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/BiologicalApprovalsbyYear/ucm596371.htm) has undergone an exponential increase. It should be noted that this data-set covers both somatic mutations and hereditary variants, together with genes that indirectly affect pharmacokinetics through drug-drug interactions